ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.

ABSTRACT:

Background

Androgen deprivation therapy (ADT) remains the leading systemic therapy for locally advanced and metastatic prostate cancers (PCa). While a majority of PCa patients initially respond to ADT, the durability of response is variable and most patients will eventually develop incurable castration-resistant prostate cancer (CRPC). Our research objective is to identify potential early driver genes responsible for CRPC development.

Methods

We have developed a unique panel of hormone-naïve PCa (HNPC) patient-derived xenograft (PDX) models at the Living Tumor Laboratory. The PDXs provide a unique platform for driver gene discovery as they allow for the analysis of differentially expressed genes via transcriptomic profiling at various time points after mouse host castration.

SUBMITTER: He H 

PROVIDER: S-EPMC8384624 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature